Key Highlights
- Collaboration Revenue was USD 132 thousand, against an estimate of USD 1.03 million.
- Net loss per share was USD 4.74, against an estimate of a USD 2.24 loss.
- Net loss widened to USD 50.02 million from USD 7.45 million.
- Cash was USD 57.94 million at September 30, 2026.
Cue Biopharma (NASDAQ:CUE) swung deeper into loss in the third quarter of 2026. The net loss was USD 50.02 million, compared with USD 7.45 million a year earlier, and net loss per share was USD 4.74, compared with USD 2.22, against an estimate of a USD 2.24 loss. Collaboration revenue fell to USD 132 thousand from USD 2.15 million, and the estimate was USD 1.03 million.
What Drove the Costs
General and administrative expense was USD 29.83 million, compared with USD 4.94 million, and Research and Development expense was USD 17.02 million, compared with USD 4.75 million. Total operating expenses were USD 47.23 million, compared with USD 9.74 million, and the loss from operations was USD 47.10 million, compared with USD 7.60 million.
Interest income was USD 483 thousand, and the change in Fair Value of financial instruments was a loss of USD 3.40 million. Weighted average shares outstanding were 10,561,814, compared with 3,362,311.
The Nine-Month Position
For the nine months ended September 30, 2026, collaboration revenue was USD 13.70 million, compared with USD 5.52 million, and total operating expenses were USD 153.84 million. The loss on issuance of Liability warrants was USD 90.01 million.
The net loss for the period was USD 208.26 million, compared with USD 28.19 million, and net loss per share was USD 28.70, compared with USD 9.37. Net cash used in Operating Activities was USD 50.0 million in one passage of the filing and USD 50.03 million in another, compared with USD 20.61 million, while net cash used in investing activities was USD 121 thousand, compared with USD 6.95 million.
Cash and Liquidity
Cash was USD 57.94 million at September 30, 2026, compared with USD 27.14 million at December 31, 2025. The company says it expects that balance to cover its projected operating needs for a minimum of twelve months after the issuance date of the financial statements.
Total Assets were USD 67.26 million, compared with USD 42.21 million, and total current assets were USD 66.71 million, compared with USD 36.98 million. Total liabilities were USD 28.86 million, compared with USD 15.78 million, and current liabilities were USD 19.73 million, compared with USD 13.49 million.
Total stockholders' Equity was USD 38.40 million, compared with USD 26.43 million, and the accumulated Deficit was USD 576.73 million, compared with USD 368.47 million. Shares outstanding were 7,753,995, compared with 3,220,707.






Please wait processing your request...